

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

**VOLUNTARY ANNOUNCEMENT –
ON THE DRUG PRODUCTION LICENSE OBTAINED BY
A WHOLLY-OWNED SUBSIDIARY**

This announcement is made by Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司) (the “**Company**”) on a voluntary basis. Please also refer to the Overseas Regulatory Announcement dated 5 December 2019 published by the Company.

The board of directors (the “**Board of Directors**”) of the Company is pleased to announce that Shanghai Junshi Biotechnology Co., Ltd.* (上海君實生物工程有限公司) (“**Junshi Biotechnology**”), a wholly-owned subsidiary of the Company, has recently received the “Drug Production License” (藥品生產許可證) approved and issued by Shanghai Medical Products Administration (上海市藥品監督管理局). The relevant situation is announced as follows:

I. MAIN INFORMATION OF THE “DRUG PRODUCTION LICENSE”

- | | |
|--|--|
| 1. Company Name: | Shanghai Junshi Biotechnology Co., Ltd.* (上海君實生物工程有限公司) |
| 2. Registered Address: | Room 1203, Building No. 2, Lane 1800, Xinyang Road, Lingang New Area, China (Shanghai) Pilot Free Trade Zone |
| 3. Production Site and Production Scope: | No. 1069, Xinyang Road, Fengxian District, Shanghai: Therapeutic Biological Product |
| 4. Permit Number: | HU20190196 (滬20190196) |
| 5. Valid until: | 24 November 2024 |
| 6. Issuing Authority: | Shanghai Medical Products Administration |

II. IMPACT ON THE COMPANY

The obtaining of the “Drug Production License” by Junshi Biotechnology will play a long-term constructive role in capacity expansion and market diversification of the Company and in the long run, it will pose positive effects on the Company’s results of operation. The Company will satisfy its obligation of information disclosures in a timely manner based on the subsequent development. Investors are advised to pay attention to investment risks.

By Order of the Board of Directors
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, PRC, 5 December 2019

As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Feng Hui, Mr. Zhang Zhuobing, Dr. Wu Hai and Dr. Yao Sheng as executive Directors; Mr. Tang Yi, Mr. Li Cong, Mr. Yi Qingqing and Mr. Lin Lijun as non-executive Directors; and Dr. Chen Lieping, Dr. He Jia, Mr. Chen Xinjun, Mr. Qian Zhi and Dr. Roy Steven Herbst as independent non-executive Directors.

** For identification purposes only*